Metis TechBio FY26 H1 loss attributable to owners narrows 20% to RMB 153.21 million; revenue jumps to RMB 154.29 million

• Metis Techbio posted revenue of RMB 154.29 million, up 13,399% year over year.
• Loss attributable to owners narrowed to RMB 153.21 million, improving 20% year over year.
• R&D expenses rose to RMB 172.37 million, up 48.1% year over year.
• Revenue from collaboration agreements climbed to RMB 153.61 million, driven by the Boulevard Bio cooperation agreement.
• Cash and cash equivalents totaled RMB 2.53 billion at June 30, 2026; cash, term deposits and FVTPL financial assets were RMB 3.03 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metis Techbio Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298080), on August 25, 2026, and is solely responsible for the information contained therein.